Skip to main navigation

Skip to main content

About
- Executive Team
- Board of Directors
- How We Operate
  Quality Capabilities
- Locations
- News
Products
Contract Manufacturing
Investors
Careers
Contact
- Contact Us
- Locations

News

Overview

Site Search

Year

08/03/2022

ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

07/28/2022

ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC

07/25/2022

ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET

07/18/2022

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary

06/22/2022

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP

06/21/2022

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

06/02/2022

ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition

06/01/2022

ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP

05/20/2022

ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences

05/10/2022

ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

Contact Us

INVESTOR CONTACT

In-Site Communications, Inc.
Lisa M. Wilson

212-452-2793
IR@anipharmaceuticals.com

Quick Links

SEC Filings
Investor FAQs
Information Request Form

Investor Email Alerts

Email Address *

Unsubscribe

Products
Investors
Careers
Contact Us
Privacy Policy
Terms of Use
Accessibility

© Copyright 2022 ANI Pharmaceuticals, Inc.

follow us on linkedin
follow us on youtube